製品番号: HY-13822

SKI II

Name: SKI II
Brand: MedChemExpress
SKU: HY-13822
Price: 72.00 USD
Availability: InStock
Rating: 5 (8 reviews)

8 Cited Publications

カスタマーレビュー

Based on 8 publication(s) in Google Scholar

SKI-II is an orally active dual-target inhibitor of SphK1/2 and DES1, with K_i values of 16 µM and 0.3 µM against SphK1 and DES1, respectively. SKI-II activates the PERK-Nrf2 antioxidant pathway by stabilizing Nrf2, and synergizes with Temozolomide (HY-17364) to induce oxidative/endoplasmic reticulum stress and cancer cell death under hypoxic conditions. In vivo, SKI-II inhibits SphK activity, promotes ceramide accumulation and apoptosis, and synergizes with Cisplatin (HY-17394) to reverse drug resistance via the ras/MAPK pathway. SKI-II reduces measles virus replication by inhibiting mTORC1 activity. SKI-II binds to VCP to induce M1 polarization, enhances host tolerance to Staphylococcus aureus infection, and exerts radioprotective effects through Nrf2 activation and accelerated DNA repair. SKI-II can be used in research related to glioblastoma, acute myeloid leukemia, gastric cancer, measles virus infection, Staphylococcus aureus infection, and acute radiation syndrome.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.25%
CAS 番号: 312636-16-1
分子式: C₁₅H₁₁ClN₂OS
分子量:302.78

保管条件:

Powder -20°C, 3 years , 4°C, 2 years

* The compound is unstable in solutions, freshly prepared is recommended.

SKI II 構造式

CAS 番号: 312636-16-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (8)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

^[3]^[8]

SphK1

16 μM (Ki)

SphK2

45 μM (IC₅₀)

DES1

0.3 μM (Ki)

SphK アイソフォーム固有の製品をすべて表示 :

SphK1
SphK2

mTOR アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	7.8 μM Compound: 13, SKI-II	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 20598402]
HeLa	EC₅₀	<1.2 μM Compound: 12	Inhibition of VCP in human HeLa cells assessed as stabilization of ubiquitin-tagged luciferase after 24 hrs by reporter gene assay Inhibition of VCP in human HeLa cells assessed as stabilization of ubiquitin-tagged luciferase after 24 hrs by reporter gene assay	[PMID: 20137940]
HeLa	IC₅₀	9.1 μM Compound: 13, SKI-II	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 20598402]
MCF-10A	IC₅₀	14.5 μM Compound: 13, SKI-II	Cytotoxicity against human MCF10A cells after 72 hrs by SRB assay Cytotoxicity against human MCF10A cells after 72 hrs by SRB assay	[PMID: 20598402]
MDA-MB-231	IC₅₀	8.2 μM Compound: 13, SKI-II	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	[PMID: 20598402]
MEF	IC₅₀	8.9 μM Compound: 13, SKI-II	Cytotoxicity against MEF after 72 hrs by SRB assay Cytotoxicity against MEF after 72 hrs by SRB assay	[PMID: 20598402]
MIA PaCa-2	IC₅₀	7.7 μM Compound: 13, SKI-II	Cytotoxicity against human MIAPaCa2 cells after 72 hrs by SRB assay Cytotoxicity against human MIAPaCa2 cells after 72 hrs by SRB assay	[PMID: 20598402]
NCI-H226	IC₅₀	8.6 μM Compound: 13, SKI-II	Cytotoxicity against human NCI-H226 cells after 72 hrs by SRB assay Cytotoxicity against human NCI-H226 cells after 72 hrs by SRB assay	[PMID: 20598402]
NCI-H441	IC₅₀	8 μM Compound: 13, SKI-II	Cytotoxicity against human H441 cells after 72 hrs by SRB assay Cytotoxicity against human H441 cells after 72 hrs by SRB assay	[PMID: 20598402]
NCI-H460	IC₅₀	9.2 μM Compound: 13, SKI-II	Cytotoxicity against human H460 cells after 72 hrs by SRB assay Cytotoxicity against human H460 cells after 72 hrs by SRB assay	[PMID: 20598402]
PBL	CC₅₀	>5 μM Compound: 99; SKI II	Cytotoxicity in human PBL cells Cytotoxicity in human PBL cells	[PMID: 33539089]
PC-3	GI₅₀	11 μM Compound: 1; SKI-II	Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay	[PMID: 26780304]
U-87MG ATCC	IC₅₀	10.7 μM Compound: 13, SKI-II	Cytotoxicity against human U87MG cells after 72 hrs by SRB assay Cytotoxicity against human U87MG cells after 72 hrs by SRB assay	[PMID: 20598402]

体外実験

SKI II (1.25 μM; 48 h) reverses the resistance of human gastric cancer SGC7901/DDP cells to Cisplatin (HY-17394)^[1].
SKI II (5-10 μM; 48 h) downregulates the expressions of P-gp, MRP1, p-ERK and p-JNK in human gastric cancer cell line SGC7901/DDP, and the effect is more significant when used in combination with Cisplatin^[1].
SKI II (5-10 μM; 48 h) reduces the protein expression levels of P-gp, MRP1, p-ERK and p-JNK in human gastric cancer cell line SGC7901/DDP, and the inhibitory effect is enhanced when used in combination with Cisplatin^[1].
SKI II (5-10 μM; 48 h) downregulates the mRNA expression of MRP1 and GST in human gastric cancer cell line SGC7901/DDP, and the inhibitory effect is enhanced when used in combination with Cisplatin^[1].
SKI II (5-10 μM; 48 h) reduces the intracellular GSH level in human gastric cancer cell line SGC7901/DDP, and its combination with cisplatin further decreases GSH level and inhibits GST activity^[1].
SKI II (0.33-5.32 μM; 5 days) inhibits the growth of human glioblastoma NCH82 cells, with an ED₅₀ of approximately 1.3 μM under both normoxic and hypoxic conditions; it also exerts a synergistic effect with Temozolomide (HY-17364)^[3].
SKI II (2.66 μM; 4 weeks) impairs the self-renewal capacity of human DMSO-1080 and temozolomide (TMZ)-resistant TMZ-1080 glioblastoma stem-like cells under both normoxic and hypoxic conditions, with an efficacy comparable to that of combined treatment with temozolomide, and its effect on TMZ-resistant GSCs is particularly pronounced under hypoxic conditions^[3].
SKI II (2.66 μM; 5 days) impairs the invasive capacity of human mesenchymal glioblastoma U3054MG spheroids under both normoxic and hypoxic conditions^[3].
SKI II (100 nM) exerts radioprotective effects by promoting the proliferation of Raw 264.7 mouse macrophages and INT-407 human intestinal epithelial cells^[6].
SKI II (100 nM; 2 h pretreatment before IR, 7-10 days) enhances the clonogenic radioresistance of Raw 264.7 mouse macrophages and INT-407 human intestinal epithelial cells^[6].
SKI II (100 nM; 2 h pretreatment prior to 2 Gy IR, 60 min-72 h post-IR) reduces ionizing radiation (IR)-induced DNA double-strand breaks and cytogenetic damage in Raw 264.7 mouse macrophages, as evidenced by decreased γ-H2AX foci and reduced micronucleus formation rate^[6].
SKI II (5 μM; 6-24 h) reduces the phosphorylation level of eIF4E in uninfected primary human peripheral blood lymphocytes (PBL), inhibits the increase in total MNK1 expression, and shows a tendency to decrease the phosphorylation level of rpS6^[2].
SKI II (100 nM-5000 nM; 48-72 h) shows no toxicity in Raw 264.7 mouse macrophages and INT-407 human intestinal epithelial cells; concentration-dependent cytotoxicity is observed only in Raw 264.7 cells at concentrations of 700 nM and higher^[6].
SKI II (5 μM; 3-24 h) reduces the expression levels of total rpS6, phosphorylated rpS6, phosphorylated eIF4E, and total IKK in primary human peripheral blood lymphocytes (PBL) infected with measles virus (MV)^[2].
SKI II (1-5 μM; 2-3 days) reduces the replication level of MV in primary human peripheral blood lymphocytes (PBLs) by approximately one log order upon infection^[2].
SKI II (5 μM; 24 h) reduces the expression of GFP and MV-H proteins in primary human peripheral blood lymphocytes (PBL) infected with measles virus (MV), while the expression of MV-N protein remains unchanged^[2].
SKI II (2.66 μM; 3-5 days) induces approximately 30% cell death in human glioblastoma NCH82 cells under normoxic conditions; when combined with Temozolomide, it further increases the proportion of cell death by approximately 30%, and its cell death-inducing effect under hypoxic conditions is significantly stronger than that of Temozolomide used alone^[3].
SKI II (2.66 μM; 48 h) hydrochloride, either used alone or in combination with Temozolomide, acts on human glioblastoma NCH82 cells under both normoxic and hypoxic conditions, reduces the levels of ceramide and its metabolites, and downregulates the ceramide/dihydrosphingosine ratio^[3].
SKI II (10 nM) binds to the ATPase domain of human VCP, as well as Caenorhabditis elegans CDC-48.1 and CDC-48.2, with nanomolar-level binding affinity, and acts as a competitive inhibitor of ATP binding^[5].
SKI II (4 μg/mL; 2-24 h) activates Nrf2-mediated oxidative stress responses in mouse RAW264.7 macrophages via a PERK-dependent pathway, reduces infection-induced reactive oxygen species levels, and decreases intracellular Staphylococcus aureus loads^[5].
SKI II (4 μg/mL; 2-24 h) promotes M1 polarization of mouse RAW264.7 macrophages, enhances their sensitivity to subsequent LPS stimulation, and induces a metabolic shift from mitochondrial oxidative phosphorylation to glycolysis^[5].
SKI II (8-32 μg/mL; 8 h-5 days) activates the SKN-1/Nrf2 pathway in Caenorhabditis elegans in a CDC-48-dependent manner, reduces infection-induced reactive oxygen species levels, and improves host survival during Staphylococcus aureus infection via a host-directed mechanism^[5].
SKI II (1 nM-1000 nM; 1 h-24 h) upregulates Nrf2 protein expression in a concentration- and time-dependent manner in Raw 264.7 mouse macrophages and INT-407 human intestinal epithelial cells^[6].
SKI II (100 nM; 2 h pretreatment prior to 2 Gy IR, 4 h-36 h post-IR) alleviates IR-induced oxidative stress in Raw 264.7 mouse macrophages by reducing ROS levels, restoring MMP, enhancing antioxidant enzyme activity and GSH levels, and upregulating the Nrf2 signaling pathway^[6].
SKI II (100 nM; pretreated for 2 h before 2 Gy irradiation and treated for 24 h after irradiation) reduces irradiation-induced apoptosis, decreases caspase-3/7 activity, and regulates the expression of pro-apoptotic and anti-apoptotic proteins in Raw 264.7 mouse macrophages^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

human gastric carcinoma SGC7901/DDP cells
Concentration:

1.25 μM (alone or in combination with DDP)
Incubation Time:

48 h
Result:

Showed no cytotoxicity against SGC7901/DDP cells when used alone.
Reduced the IC₅₀ of DDP against SGC7901/DDP cells from 3.33 μM to 2.062 μM when used in combination with DDP.
Resulted in a 1.615-fold reversal of DDP resistance when used in combination with DDP.

Western Blot Analysis^[1]

Cell Line:

human gastric carcinoma SGC7901/DDP cells
Concentration:

5 and 10 μM (alone or in combination with 2.5 mg/l DDP)
Incubation Time:

48 h
Result:

Significantly reduced the OD values (indicating decreased protein expression) of P-gp, MRP1, p-ERK, and p-JNK in SGC7901/DDP cells when used alone at 5 μM and 10 μM compared to control or DDP-only groups.
Caused a greater reduction in OD values when combined with 2.5 mg/l DDP compared to SKI‑Ⅱ alone.

RT-PCR^[1]

Cell Line:

human gastric carcinoma SGC7901/DDP cells
Concentration:

5 and 10 μM (alone or in combination with 2.5 mg/l DDP)
Incubation Time:

48 h
Result:

Significantly decreased MRP1 and GST mRNA expression in SGC7901/DDP cells when used alone at 5 μM and 10 μM.
Caused a greater reduction in MRP1 and GST mRNA expression when combined with 2.5 mg/l DDP compared to SKI‑Ⅱ alone.

Cell Proliferation Assay^[3]

Cell Line:

human glioblastoma NCH82 cells
Concentration:

0.33, 0.66, 1.33, 2.66 and 5.32 μM; 2.66 μM (in combination with 48 μM Temozolomide)
Incubation Time:

5 days
Result:

Inhibited NCH82 cell growth with an ED₅₀ of approximately 1.3 μM under both normoxia and hypoxia.
Synergistically inhibited cell growth by almost 80% under both oxygen conditions when used at 2.66 μM in combination with 48 μM temozolomide, with a combination index of 0.45 under normoxia and 0.51 under hypoxia.

Apoptosis Analysis^[3]

Cell Line:

human glioblastoma NCH82 cells
Concentration:

2.66 μM; 2.66 μM (in combination with 48 μM Temozolomide)
Incubation Time:

3 days; 5 days
Result:

Induced approximately 30% cell death (Annexin V-FITC+/PI− and Annexin V-FITC+/PI+ cells) after 3 and 5 days under normoxia.
Enhanced cell death by about 30% after 5 days under normoxia when combined with 48 μM temozolomide compared to single treatments.
Induced similar cytotoxicity to temozolomide alone after 3 days under hypoxia; significantly potentiated cell death compared to temozolomide alone after 5 days under hypoxia when combined with 48 μM temozolomide.

Cell Invasion Assay^[3]

Cell Line:

human mesenchymal glioblastoma U3054MG cells
Concentration:

2.66 μM; 2.66 μM (in combination with 48 μM Temozolomide)
Incubation Time:

5 days
Result:

Reduced U3054MG spheroid invasion by about 30-40% after 5 days under both normoxia and hypoxia.
Yielded similar invasion reduction to SKI II (hydrochloride) alone when combined with 48 μM temozolomide.

Cell Viability Assay^[6]

Cell Line:

Raw 264.7 mouse macrophage cells, INT-407 human intestinal epithelial cells
Concentration:

100, 200, 500, 700, 1000, 2000 and 5000 nM
Incubation Time:

48 h (Raw 264.7); 72 h (INT-407)
Result:

Showed no cytotoxicity at concentrations up to 500 nM in Raw 264.7 cells.
Induced concentration-dependent cytotoxicity at 700 nM to 5000 nM in Raw 264.7 cells.
Exhibited no toxicity at all tested concentrations in INT-407 cells.

Western Blot Analysis^[6]

Cell Line:

Raw 264.7 mouse macrophage cells, INT-407 human intestinal epithelial cells
Concentration:

1, 10, 100, 200, 500 and 1000 nM (2 h incubation); 100 nM (1 h, 2 h, 4 h, 6 h, 8 h, 24 h incubation)
Incubation Time:

1 h, 2 h, 4 h, 6 h, 8 h, 24 h
Result:

Significantly upregulated Nrf2 expression at all tested concentrations in Raw 264.7 cells, with maximum ~1.8-fold relative to control at 100 nM.
Significantly upregulated Nrf2 expression first detected at 2 h and persisted up to 24 h with 100 nM treatment in Raw 264.7 cells.
Significantly upregulated Nrf2 expression at all tested concentrations in INT-407 cells, with maximum ~2.8-fold relative to control at 200 nM.
Significantly upregulated Nrf2 expression first detected at 1 h and persisted up to 24 h with 100 nM treatment in INT-407 cells.

Cell Proliferation Assay^[6]

Cell Line:

Raw 264.7 mouse macrophage cells, INT-407 human intestinal epithelial cells, IEC-6 rat intestinal epithelial cells, NIH/3T3 mouse fibroblast cells
Concentration:

100 nM
Incubation Time:

2 h pretreatment before IR; 24 h, 48 h post-2 Gy IR (Raw 264.7); 24 h, 48 h, 72 h post-6 Gy IR (INT-407, IEC-6); 24 h, 48 h, 72 h post-4 Gy IR (NIH/3T3)
Result:

Significantly increased cell proliferation relative to IR-only treatment in all cell lines.
Increased proliferation index by 43% at 48 h post-2 Gy IR in Raw 264.7 cells compared to IR-only cells.
Increased proliferation index by ~39% at 72 h post-IR in INT-407, IEC-6, and NIH/3T3 cells compared to IR-only cells.

Apoptosis Analysis^[6]

Cell Line:

Raw 264.7 mouse macrophage cells
Concentration:

100 nM
Incubation Time:

2 h pretreatment before 2 Gy IR; 24 h post-IR analysis
Result:

Reduced percentage of dead cells relative to IR-only treatment.
Decreased total apoptotic cells (early + late) from 53.3% (IR-only) to 24.7% (SKI-II + IR).
Significantly lowered caspase-3/7 activity compared to IR-only cells.
Reduced cleaved PARP and p53 expression (1.4-fold vs. 4-fold relative to control in IR-only).
Reduced pro-apoptotic Bax expression relative to IR-only cells.
Increased anti-apoptotic Bcl-xL expression relative to IR-only cells.

体内実験

SKI II (0.3 mg/kg; i.p.; single administration; 48 h exposure) alone reduces the expressions of P-gp, MRP1, p-ERK, p-JNK, GSH and GST in tumor tissues of subcutaneous gastric cancer nude mouse models, and enhances the effects of Cisplatin (HY-17394) on these targets^[1].

Hydrochloride of SKI II (10-50 mg/kg; intraperitoneal injection; once daily; for 7 consecutive days) dose-dependently inhibits the growth of U937 acute myeloid leukemia xenografts in SCID/beige mice without inducing obvious toxicity^[4].
Treatment with SKI II (50.0 mg/kg, i.p.; 100 mg/kg, p.o.) reduces tumor growth in mice bearing solid tumor models^[7].
SKI II (4-32 μg/mL; liquid incubation; 8-24 hours; liquid infection assay; 5 days) activates the SKN-1/Nrf2 pathway in Caenorhabditis elegans, thereby reducing pathogenic ROS, restoring physiological functions, and improving survival rate during Staphylococcus aureus infection^[5].
Hydrochloride form of SKI II (0.1 mg/kg; i.p.; administered once before irradiation and once every 24 h after irradiation, for a total of 3 doses) exerts radioprotective effects on C57BL/6 mice exposed to lethal ionizing radiation^[6].
Hydrochloride form of SKI II (0.1 mg/kg; i.p.; administered once before irradiation, followed by once every 24 h post-irradiation until 72 h post-irradiation) protects C57BL/6 mice against radiation-induced cytopenia by reducing initial cytopenia and promoting hematopoietic recovery^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/C nude (female, 4 weeks old, 15-19 g, subcutaneous implantation of human gastric cancer SGC7901/DDP cells)^[1]
Dosage:

0.3 mg/kg (single agent); 0.3 mg/kg + 2.5 mg/kg (combination with Cisplatin)
Administration:

i.p.; single dose; 48-hour exposure
Result:

Reduced protein expression rates of P-gp (51.503%), MRP1 (50.624%), p-ERK (52.500%), and p-JNK (52.173%) via immunohistochemistry.
Reduced optical density values of P-gp (1.047), MRP1 (0.997), p-ERK (0.813), and p-JNK (0.817) via western blotting.
Reduced tumor GSH content.
Further reduced protein expression rates of P-gp (45.637%), MRP1 (42.321%), p-ERK (44.534%), and p-JNK (46.040%) via immunohistochemistry when combined with Cisplatin.
Further reduced optical density values of P-gp (0.870), MRP1 (0.810), p-ERK (0.713), and p-JNK (0.680) via western blotting when combined with Cisplatin.
Further reduced tumor GSH content and reduced tumor GST activity when combined with Cisplatin.

Animal Model:

CB17 severe combined immunodeficient (SCID)/beige (6-week-old)^[4]
Dosage:

10 mg/kg; 50 mg/kg
Administration:

i.p.; daily; 7 consecutive days
Result:

Reduced mean U937 tumor volume by 50% relative to vehicle controls at day 10.
Reduced mean U937 tumor volume by over 75% relative to vehicle controls at day 10.
Lowered tumor weights relative to vehicle controls at euthanasia.
Showed no signs of wasting, with body weights not different from vehicle controls.

Animal Model:

AU37 [glp-4(bn2);sek-1(km4)]^[5]
Dosage:

4 μg/mL (gst-4 activation assay, 8 hours); 8 μg/mL (gst-4 activation assay, 16/24 hours; infection survival assay, 5 days); 16 μg/mL (gst-4 activation assay, 16/24 hours; infection survival assay, 5 days; ROS measurement, 3 days; SKN-1 expression analysis, 24 hours; pharyngeal pumping measurement, 24 hours); 32 μg/mL (gst-4 activation assay, 16/24 hours)
Administration:

liquid incubation (8, 16, 24 hours); liquid infection assay (5 days)
Result:

Increased survival of Caenorhabditis elegans during S. aureus infection at 8, 16, or 32 μg/mL.
Induced a modest increase in gst-4p::gfp expression after 8 hours at 4 μg/mL.
Sustained increased gst-4p::gfp expression after 16 and 24 hours at 8, 16, and 32 μg/mL.
Reduced ROS levels in S. aureus-infected Caenorhabditis elegans to levels comparable to vancomycin treatment at 16 μg/mL.
Increased the percentage of skn-1B/C::gfp Caenorhabditis elegans with high SKN-1 expression from 3.7% to 44.4% at 16 μg/mL.
Abolished gst-4p::gfp expression and protective effects during infection when SKN-1 was knocked down.
Restored near-normal pharyngeal pumping in S. aureus-infected *Caenorhabditis elegans* and increased intestinal S. aureus load while improving survival at 16 μg/mL.

Animal Model:

C57BL/6 (adult female, 6-8 weeks old, average weight 22-25 g, whole-body exposure to single lethal 7.5 Gy ionizing radiation)^[6]
Dosage:

0.1 mg/kg
Administration:

i.p.; 1 dose 2 hours pre-irradiation, plus 3 doses at 24-hour intervals post-irradiation
Result:

Achieved 75% survival rate at 30 days post-irradiation.

Animal Model:

C57BL/6 (adult female, 6-8 weeks old, average weight 22-25 g, whole-body exposure to single 2 Gy ionizing radiation)^[6]
Dosage:

0.1 mg/kg
Administration:

i.p.; 1 dose 2 hours pre-irradiation, plus additional doses at 24-hour intervals up to 72 hours post-irradiation
Result:

Reduced initial dip in white blood cell counts to 3.145 × 10⁹/L at 24 hours post-irradiation.
Accelerated white blood cell recovery starting at day 14, with nearly restored baseline levels by day 28.
Reduced initial dip in lymphocyte counts, with complete recovery by day 21.
Initiated granulocyte recovery at day 7.
Induced earlier platelet count incline at day 7 compared to irradiated-only mice.
Caused no changes in red blood cell counts across groups.

Animal Model:

BALB/c mouse solid tumor model that uses JC mammary adenocarcinoma cells^[7]
Dosage:

50.0 mg/kg
Administration:

IP injection daily, 3 days a week for 16 weeks.
Result:

Had strong inhibition of tumor growth from the start of treatment of 65%, with no toxicity or weight loss.

Animal Model:

BALB/c JC tumor model^[7]
Dosage:

100 mg/kg
Administration:

PO every other day
Result:

Caused significant antitumor activity in well-established tumors as early as day 5, with maximal response seen at the end of the study. Showed 79% inhibition of tumor growth from the start of treatment.

化学情報

CAS 番号 312636-16-1
性状 Solid
分子量 302.78
分子式 C₁₅H₁₁ClN₂OS
Color White to off-white
SMILES

OC1=CC=C(NC2=NC(C3=CC=C(Cl)C=C3)=CS2)C=C1
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years

* The compound is unstable in solutions, freshly prepared is recommended.

Publications (8)

All Flow CytometryOthersWBIF

Sort by:

Journal Impact Factor

Cancer Commun (Lond)

Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis. [Abstract]

2025 Jul 16. PMID: 40665874

SKI II purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Jul 16. [Abstract]

IF staining showed that the liver tumors with PF543 or SKI II (50 mg/kg) treatment exhibited a decreased number of phosphorylated SPHK1+ TAMs (activated SPHK1) in the TME.
Autophagy

Mitophagy-mediated S1P facilitates muscle adaptive responses to endurance exercise through SPHK1-S1PR1/S1PR2 in slow-twitch myofibers. [Abstract]

2025 Apr 3. PMID: 40181214

SKI II purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Apr 3. [Abstract]

Quantification of S1P concentrations in C2C12 myotubes treated with 10 μM FCCP for 4 h with/without 50 μM NOE or 5 μM SKI-II pre-treatment (n = 4).

SKI II purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Apr 3. [Abstract]

PPARGC1A protein levels in the C2C12 myotubes 48 h after the stimulation of 10 μM FCCP with/without 5 μM SKI-II in the absence or presence of 5 μM S1P (n = 4).
Cell Commun Signal

Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis. [Abstract]

2024 Aug 7;22(1):391. PMID: 39113090

SKI II purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2024 Aug 7;22(1):391. [Abstract]

Western blot analysis of Molm13 cells after treatment with the indicated concentrations of SKI-II for 24, 48, and 72 h.

SKI II purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2024 Aug 7;22(1):391. [Abstract]

Apoptosis in Molm13 and MV4-11 cells pretreated with or without exogenous BSA-conjugated S1P (1 µM, added once every 3 h for 24 h) for 2 h, followed by treatment with SKI-II (25 µM) for 24 h.
Mol Med Rep

Notoginsenoside R1 ameliorates the inflammation induced by amyloid‑β by suppressing SphK1‑mediated NF‑κB activation in PC12 cells. [Abstract]

2024 Jan;29(1):16. PMID: 38063180
J Virol

Epithelial-to-mesenchymal transition and live cell extrusion contribute to measles virus release from human airway epithelia. [Abstract]

2025 Feb 25;99(2):e0122024. PMID: 39791903
Cell Biol Int

Bone marrow mesenchymal stem cells-derived exosomes reduce Aβ deposition and improve cognitive function recovery in mice with Alzheimer's disease by activating sphingosine kinase/sphingosine-1-phosphate signaling pathway. [Abstract]

2021 Apr;45(4):775-784. PMID: 33300254
J Leukoc Biol

Microvesicles derived from activated T cells promote human mast cell migration via the S1P1 receptor. [Abstract]

2025 Aug 5;117(8):qiaf111. PMID: 40743264
bioRxiv

2024 July 15.

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (330.27 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3027 mL

16.5136 mL

33.0273 mL

5 mM

0.6605 mL

3.3027 mL

6.6055 mL

10 mM

0.3303 mL

1.6514 mL

3.3027 mL

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.75 mg/mL (9.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.75 mg/mL (9.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (318 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Liu Y, et al. SKI-II reverses the chemoresistance of SGC7901/DDP gastric cancer cells. Oncology letters. 2014 Jul;8(1):367-373. [Content Brief]

[2]. Chithelen J, et al. The Sphingolipid Inhibitors Ceranib-2 and SKI-II Reduce Measles Virus Replication in Primary Human Lymphocytes: Effects on mTORC1 Downstream Signaling. Frontiers in physiology. 2022;13:856143.

[3]. Sousa N, et al. Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion. BMC cancer. 2023 Aug 16;23(1):762.

[4]. Yang L, et al. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo. Biochemical and biophysical research communications. 2015 May 15;460(4):903-8.

[5]. Zhang L, et al. Identification of SKI-II as a host-protective immunomodulator against Staphylococcus aureus infection. mBio. 2026 Aug 10:e0155826.

[6]. Sah DK, et al. Sphingosine kinase inhibitor, SKI-II confers protection against the ionizing radiation by maintaining redox homeostasis most likely through Nrf2 signaling. Life sciences. 2021 Aug 01;278:119543.

[7]. French KJ, et al. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006 Aug;318(2):596-603.

[8]. Potì F, et al. SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis. 2015 May;240(1):212-5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3027 mL	16.5136 mL	33.0273 mL	82.5682 mL
	5 mM	0.6605 mL	3.3027 mL	6.6055 mL	16.5136 mL
	10 mM	0.3303 mL	1.6514 mL	3.3027 mL	8.2568 mL
	15 mM	0.2202 mL	1.1009 mL	2.2018 mL	5.5045 mL
	20 mM	0.1651 mL	0.8257 mL	1.6514 mL	4.1284 mL
	25 mM	0.1321 mL	0.6605 mL	1.3211 mL	3.3027 mL
	30 mM	0.1101 mL	0.5505 mL	1.1009 mL	2.7523 mL
	40 mM	0.0826 mL	0.4128 mL	0.8257 mL	2.0642 mL
	50 mM	0.0661 mL	0.3303 mL	0.6605 mL	1.6514 mL
	60 mM	0.0550 mL	0.2752 mL	0.5505 mL	1.3761 mL
	80 mM	0.0413 mL	0.2064 mL	0.4128 mL	1.0321 mL
	100 mM	0.0330 mL	0.1651 mL	0.3303 mL	0.8257 mL

Bioz

SKI II

8 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

SKI II

MedChemExpress（MCE）の使用を引用している文献 SKI II

SphK アイソフォーム固有の製品をすべて表示

mTOR アイソフォーム固有の製品をすべて表示

生物活性